Consensus on Prostate Cancer Treatment of Localized Disease With Very Low, Low, and Intermediate Risk: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC) ...

Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved piflufolastat (18F) (Pylclari, Curium Pharma) as a diagnostic tool for people with suspected or known prostate cancer. It ...

FDA-authorized AI tools have the potential to help patients with prostate cancer get clearer answers instead of waiting weeks for genomic test results. FDA-authorized artificial intelligence (AI) ...

Researchers identify APOC1 and NOP16 as promising prostate cancer biomarkers that could aid early diagnosis. Learn more about ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Brisbane-based medical practice management software provider Genie Solutions and men's health charity the Movember Foundation announced a partnership to provide a suite of digital tools to help men ...